Table 1.
Demographic and clinical information of the autopsied cases.
| LBD | Control | AD | |
|---|---|---|---|
| Demographics | |||
| Participants, N | 15 | 6 | 7 |
| Age at Death, y | 81 (71‐93) | 84 (70‐100) | 73 (62‐78) |
| Male/Female, N | 12/3 | 2/4 | 4/3 |
| Clinical characteristics of LBD participants | |||
| Age at LBD diagnosis, y | 63 (54–82) | NA | NA |
| Duration of motor impairment, y | 14 (8–27) | NA | NA |
| UPDRS‐III score (OFF medications) | 44 (35–73.5) | NA | NA |
| LEDD, mg | 800 (0–1350) | NA | NA |
| SSRI medications, N | 10/15 | NA | NA |
| Other antidepressant medications, N a | 2/15 | NA | NA |
| AChE inhibitor medications, N b | 8/15 | NA | NA |
| Neuroleptic medications, N c | 14/15 | NA | NA |
Abbreviations: AChE, acetylcholinesterase. Values are median (range) unless otherwise indicated; LEDD, levodopa equivalent daily dose; NA, not applicable; SSRI, selective serotonin reuptake inhibitors; UPDRS, Unified Parkinson Disease Rating Scale; Y, years.
a
Mirtazapine and venlafaxine.
b
Donepezil, rivastigmine, and galantamine.
c
Quetiapine and clozapine.